187 related articles for article (PubMed ID: 1839490)
1. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity.
Kureishi A; Jewesson PJ; Rubinger M; Cole CD; Reece DE; Phillips GL; Smith JA; Chow AW
Antimicrob Agents Chemother; 1991 Nov; 35(11):2246-52. PubMed ID: 1839490
[TBL] [Abstract][Full Text] [Related]
2. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients.
Chow AW; Jewesson PJ; Kureishi A; Phillips GL
Eur J Haematol Suppl; 1993; 54():18-24. PubMed ID: 8365461
[TBL] [Abstract][Full Text] [Related]
3. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial.
Peacock JE; Herrington DA; Wade JC; Lazarus HM; Reed MD; Sinclair JW; Haverstock DC; Kowalsky SF; Hurd DD; Cushing DA; Harman CP; Donowitz GR
Ann Intern Med; 2002 Jul; 137(2):77-87. PubMed ID: 12118962
[TBL] [Abstract][Full Text] [Related]
4. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
[TBL] [Abstract][Full Text] [Related]
5. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
[TBL] [Abstract][Full Text] [Related]
7. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
[TBL] [Abstract][Full Text] [Related]
8. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients.
Cony-Makhoul P; Brossard G; Marit G; Pellegrin JL; Texier-Maugein J; Reiffers J
Br J Haematol; 1990 Dec; 76 Suppl 2():35-40. PubMed ID: 2149050
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer.
Rolston KV; Nguyen H; Amos G; Elting L; Fainstein V; Bodey GP
J Infect Dis; 1994 Feb; 169(2):350-5. PubMed ID: 8106768
[TBL] [Abstract][Full Text] [Related]
10. Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients.
Kureishi A; Jewesson PJ; Bartlett KH; Cole CD; Chow AW
Antimicrob Agents Chemother; 1990 Sep; 34(9):1642-7. PubMed ID: 2149492
[TBL] [Abstract][Full Text] [Related]
11. Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients.
Rotstein C; Cimino M; Winkey K; Cesari C; Fenner J
Am J Med; 1988 Jul; 85(1A):36-43. PubMed ID: 3041817
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of once- versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation.
Sung L; Dupuis LL; Bliss B; Taddio A; Abdolell M; Allen U; Rolland M; Tong A; Taylor T; Doyle J
J Natl Cancer Inst; 2003 Dec; 95(24):1869-77. PubMed ID: 14679156
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis.
Martino P; Micozzi A; Gentile G; Raccah R; Girmenia C; Mandelli F
Clin Infect Dis; 1992 Aug; 15(2):290-4. PubMed ID: 1387806
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients.
Kelsey SM; Collins PW; Delord C; Weinhard B; Newland AC
Br J Haematol; 1990 Dec; 76 Suppl 2():10-3. PubMed ID: 2149044
[TBL] [Abstract][Full Text] [Related]
15. Role of glycopeptide antibiotics in the treatment of febrile neutropenic patients.
Smith SR; Cheesbrough J; Harding I; Davies JM
Br J Haematol; 1990 Dec; 76 Suppl 2():54-6. PubMed ID: 2149054
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W
Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836
[TBL] [Abstract][Full Text] [Related]
18. [The use of teicoplanin in neutropenic patients: values and limits].
Espinouse D; Chomarat M
Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):552-6. PubMed ID: 2143573
[TBL] [Abstract][Full Text] [Related]
19. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Hess U; Böhme C; Rey K; Senn HJ
Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.
Cometta A; Kern WV; De Bock R; Paesmans M; Vandenbergh M; Crokaert F; Engelhard D; Marchetti O; Akan H; Skoutelis A; Korten V; Vandercam M; Gaya H; Padmos A; Klastersky J; Zinner S; Glauser MP; Calandra T; Viscoli C;
Clin Infect Dis; 2003 Aug; 37(3):382-9. PubMed ID: 12884163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
